How to Help Your Patients Save Money on Ingrezza: A Provider's Guide to Savings Programs

Ingrezza (valbenazine) carries a retail price of approximately $7,900–$8,700 per month — placing it in the top tier of specialty medication costs. For prescribers, this creates a significant patient adherence challenge. When patients cannot afford their medication, they stop taking it. Understanding the full landscape of available savings programs is essential for keeping patients on therapy and achieving long-term treatment success.

Overview: Ingrezza Cost Assistance Programs in 2026

Neurocrine Biosciences administers financial assistance programs for Ingrezza through its Neurocrine Access Support program (previously branded as INBRACE). As of mid-2025, Neurocrine reports coverage approval for more than 8 in 10 patients nationwide. The key programs are:

INBRAZE / Neurocrine Savings Card (commercial insurance)

Patient Assistance Program (PAP) (uninsured/qualifying financial need)

INGREZZA Start Program (free 30-day trial for new patients)

Medicare Extra Help (LIS) (low-income Medicare patients)

Program 1: INBRACE / Neurocrine Savings Card (Commercial Insurance)

The Neurocrine Savings Card is your most powerful tool for commercially insured patients. When properly enrolled, eligible patients pay as little as $0 per month.

Eligibility: Commercial (non-government) insurance only. Not valid for Medicare, Medicaid, TRICARE, or other federally funded plans.

Enrollment: Automatically activated when your office submits the INGREZZA Treatment Form. Can also be initiated by calling 1-844-647-3992.

Savings impact: Reduces most commercially insured patients to $10 or less per month. The savings card is applied at the specialty pharmacy counter, reducing the patient's share to the program limit.

Clinical note: Neurocrine reports the $0 copay program can make Ingrezza out-of-pocket costs lower than generic alternatives for eligible patients.

Program 2: Patient Assistance Program (PAP)

The Neurocrine Patient Assistance Program provides Ingrezza at no cost to patients who:

Are uninsured or lack prescription drug coverage, OR

Demonstrate a qualifying financial need (income-based)

Your office can initiate the PAP application by submitting required income documentation through the INGREZZA Treatment Form process, or by calling 1-844-647-3992. Your practice's intake coordinator can streamline this by collecting financial information at the time of the first Ingrezza appointment.

Program 3: INGREZZA Start Program (30-Day Free Trial)

The INGREZZA Start Program (formerly the 30-Day Free Trial) provides a free 1-month supply for new patients. This is an invaluable clinical tool because:

It allows treatment to start immediately while prior authorization is being processed.

It reduces the "will this work for me?" cost concern that can make patients reluctant to start a new specialty medication.

It allows assessment of tolerability at the initial 40 mg dose before committing to ongoing therapy.

To enroll: download the enrollment form from ingrezza.neurocrineaccesssupport.com and submit on behalf of your patient. The free supply cannot be submitted for insurance reimbursement.

Program 4: Medicare Patients — Maximizing Coverage

Approximately 46% of Medicare Part D plans cover Ingrezza. The commercial savings card is not valid for Medicare patients. However, several other cost-reduction strategies apply:

Out-of-pocket cap: In 2026, Medicare Part D has a $2,100 annual out-of-pocket maximum. Once reached, the plan covers 100% of covered drug costs for the rest of the year.

Extra Help (Low Income Subsidy): Low-income Medicare patients may qualify for the Extra Help program, which dramatically reduces or eliminates Part D premiums, deductibles, and copays. Help your patients apply at SSA.gov or call 1-800-MEDICARE.

Medicare Prescription Payment Plan: Effective January 2025, Medicare patients can spread their annual prescription drug costs over monthly payments rather than paying large upfront costs early in the year.

Plan switching: During annual Medicare Open Enrollment (October 15–December 7), help patients switch to a Part D plan that covers Ingrezza at a lower tier, if available in their area.

Recommended Practice Workflow

For maximum patient success, implement this workflow at the time of prescribing Ingrezza:

Submit the INGREZZA Treatment Form (automatically enrolls in savings card and PA support).

Enroll new patients in the 30-Day Free Trial to start therapy immediately.

For uninsured/underinsured patients, collect financial documentation and apply for the PAP at the same visit.

For Medicare patients, provide information about Extra Help and the prescription payment plan.

Set EHR reminders for annual PA renewals 30–60 days in advance to avoid coverage gaps.

For patients who have insurance in place but still need help finding which pharmacy can fill their Ingrezza, medfinder calls pharmacies on behalf of your patients to locate which ones can fill the prescription. This saves time for your staff and reduces patient frustration.

See also: How to help your patients find Ingrezza in stock: A provider's guide.